Free public records show Hangzhou Valgen Medtech Co., Ltd in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Hangzhou Valgen Medtech Co., Ltd or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
6 active studies led by Hangzhou Valgen Medtech Co., Ltd, of 12 in all
Source: ClinicalTrials.gov, Studies with Hangzhou Valgen Medtech Co., Ltd (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Hangzhou Valgen Medtech Co., Ltd leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Hangzhou Valgen Medtech Co., Ltd or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Hangzhou Valgen Medtech Co., Ltd: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Hangzhou Valgen Medtech Co., Ltd is in.
Stories on the topics Hangzhou Valgen Medtech Co., Ltd works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
Read
In 2017 India capped coronary stent prices, cutting drug-eluting stent prices by about 85%. Heart disease is…
ReadSearch all reports for Hangzhou Valgen Medtech Co., Ltd All companies